Browse News
Filter News
Found 808,308 articles
-
Read the latest overview of people coming and going from executive positions at biopharma companies covered by BioSpace.
-
Despite the strong performance of its cancer portfolio, Johnson & Johnson on Tuesday reported Stelara sales of $2.45 billion in the first quarter of 2024, falling short of Wall Street expectations of $2.6 billion.
-
Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.
-
The German biopharma company on Tuesday announced ambitious pipeline plans that include starting 10 new Phase II and III trials over the next 12 to 18 months.
-
Novartis on Monday shared late-stage data for its potential multibillion-dollar drug Fabhalta, in what the company contends is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in IgA nephropathy patients.
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
In a Phase I/II study, Ultragenyx’s antisense oligonucleotide GTX-102 led to significant cognitive, behavioral, sleep and gross motor improvements in patients with the rare genetic disorder Angelman syndrome.
-
A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged patent infringement related to their COVID-19 vaccine Comirnaty.
-
Already approved in schizophrenia and bipolar depression, Intra-Cellular Therapies reported strong late-stage data Tuesday for its antipsychotic Caplyta in major depressive disorder.
-
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
4/16/2024
Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO.
-
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
4/16/2024
Palisade Bio, Inc. announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108.
-
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
4/16/2024
Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY.
-
Propanc Biopharma Receives Certificate of Grant for “Composition of Proenzymes for Cancer Treatment” Patent from European Patent Office
4/16/2024
Propanc Biopharma, Inc. today announced that a certificate of grant for the Company’s “composition of proenzymes for cancer treatment,” patent was received from the European Patent Office.
-
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
4/16/2024
Petros Pharmaceuticals, Inc. announces it has received positive feedback from the U.S. Food and Drug Administration following the FDA's informal review of Petros' technology component for self-selection as the Company endeavors to achieve OTC status for STENDRA.
-
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
4/16/2024
PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies of drugs used routinely to save lives in that region of Africa.
-
Pelthos Therapeutics Establishes Board of Directors
4/16/2024
Pelthos Therapeutics today announced it has appointed five seasoned industry professionals to serve on its Board of Directors.
-
n-Lorem Foundation Collaborates with Across Healthcare to Develop a Custom Submission Platform for Physicians of Nano-rare Patients
4/16/2024
n-Lorem, a nonprofit Foundation , has collaborated with Across Healthcare, a technology innovator, to develop a first-of-its-kind submission platform and system that allows research physicians from across the United States to submit applications for treatment for their patients with nano-rare illnesses.
-
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
4/16/2024
Mabwell presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10, 2024.
-
NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development
4/16/2024
NMDP BioTherapies ℠, formerly Be The Match BioTherapies unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings.
-
Turnstone Biologics Appoints William Waddill to its Board of Directors
4/16/2024
Turnstone Biologics Corp. today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.